Tandem 10-Q: Q3 Sales $283.7M, Net Loss $7.1M; Cash $443.1M, Debt $603.4M
TNDM sits 63% above its 52-week low of $12.26.
Summary
Tandem's Q3 10-Q confirms 14% sales growth to $283.7 million and a narrowed $7.1 million net loss, with $443.1 million of liquidity against $603.4 million of convertible notes and a supplier constraint expected to last into early 2027.
Key Events · Earnings and Guidance · TNDM
-
Q3 Sales Up 14% to $283.7M
Worldwide sales rose to $283.7 million from $249.3 million, with U.S. sales of $191.0 million and international sales of $92.6 million; gross margin improved to 57% from 54%.
-
Net Loss Narrowed to $7.1M
Net loss was $7.1 million, or $0.10 per share, versus $21.2 million a year earlier, helped by the absence of last year's $75.2 million IPR&D and $20.0 million litigation charges.
-
Liquidity $443.1M vs $603.4M Debt
Cash and cash equivalents plus short-term investments totaled $443.1 million at September 30, 2026; convertible notes rose to $603.4 million net from $310.0 million at December 31, 2025 after the $300.0 million 0% 2032 notes.
-
Supplier Constraint Into Early 2027
A key infusion set supplier's supply challenges have hit inventory and supply sales, and the company expects the constraints to persist through early 2027.
Analysis · TNDM · Industrial Applications And Services
The 10-Q confirms the quarter the 8-K previewed — sales up 14% to $283.7 million and the net loss narrowed to $7.1 million from $21.2 million — but it also carries the balance-sheet detail investors need to judge the story. Liquidity of $443.1 million (cash plus short-term investments) covers at least the next twelve months, against $603.4 million of convertible notes that nearly doubled after the February 2026 zero-coupon 2032 issuance. The offsetting risk is operational: a key infusion set supplier's constraints are now expected to persist through early 2027, capping supply sales, and the pharmacy-channel shift is still depressing upfront pump revenue while supply revenue scales. The filing also formalizes the CEO handover to Jeannette Bankes effective November 16, 2026, with a $10.0 million RSU award and $900,000 base salary.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TNDM was trading at $20.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $12.26 to $29.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.